Stay updated on Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the webpage content.
    Difference
    0.3%
    Check dated 2024-06-13T21:43:07.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the context of medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-06-06T14:38:15.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 04 6 to 05 7, indicating an update in the study record or documentation related to medical and healthcare publications. This change may reflect a new version or an update in the clinical trial information provided by Regeneron Pharmaceuticals.
    Difference
    0.6%
    Check dated 2024-05-22T21:12:13.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T21:54:59.000Z thumbnail image

Stay in the know with updates to Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.